Journals / Çocuk Dergisi / 2012 / Cilt: 12 - Sayı: 1

Childhood Acute Lymphoblastic Leukemia

Çocukluk Çağı Akut Lenfoblastik Lösemisi

Pages
6–15
Publication Date
2012-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As the understanding of acute lymphoblastic leukemia improves in the future, then survival rates will increase further

📌 3 Key Takeaways

🎯
Objective & Hypothesis:While cancer is the second most common cause of death in children in many developed countries, it ranks among the first four in Turkey.
📊
Key Findings & Data:The most common subtype, ie. acute lymphoblastic leukemia constitutes 75-80 % of all childhood leukemia cases.
💡
Conclusion & Impact:As the understanding of acute lymphoblastic leukemia improves in the future, then survival rates will increase further
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akut lenfoblastik lösemi · çocuk · tedavi

Abstract

While cancer is the second most common cause of death in children in many developed countries, it ranks among the first four in Turkey. Leukemia, which is the malign prolife- ration and accumulation of lymphopoetic cells, is the most common childhood cancer. The most common subtype, ie. acute lymphoblastic leukemia constitutes 75-80 % of all childhood leukemia cases. Acute lymphoblastic leukemia with a yearly incidence of 34.4 per million in Turkey is treated with a protocol that includes induction of remission, intensification consolidation and maintenance phases. Nowadays with reinforced treatment modalities, 5-year event-free survival is reported to be over 80 %. As the understanding of acute lymphoblastic leukemia improves in the future, then survival rates will increase further

Özet

Birçok gelişmiş ülkede çocuklarda en yaygın ikinci ölüm nedeni olan kanser, ülkemizde ilk dört sıra içinde yer almaktadır. İmmatür lenfohematopoetik hücrelerin malign proliferasyonu ve birikimi olan lösemi, en sık görülen çocukluk çağı kanseridir. En sık görülen alt tipi olan akut lenfoblastik lösemi, vakaların % 75-80’ini oluşturur. Ülkemizde yıllık insidans hızı milyonda 34.4 olan akut len- foblastik lösemi remisyon indüksiyonu, intensifikasyon konsolidasyon ve idame fazlarından oluşan bir protokol ile tedavi edilir. Güçlendirilmiş tedaviler ile günümüzde beş yıllık olaysız sağ kalım % 80’in üzerinde bildirilmekte- dir. Akut lenfoblastik lösemi daha iyi anlaşıldıkça gelecekte sağ kalım oranları daha da artacaktır

🔖

Cite This Article

KARAKAŞ, Z., UZUNHAN, T. A. (2012). Childhood Acute Lymphoblastic Leukemia. Çocuk Dergisi, Cilt: 12 - Sayı: 1, 6–15. https://ajindex.com/articles/247063

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Zuelzer WW, Inoue S, Thompson RI, et al. Long-term cytogenetic studies in acute leukemia of children: the nature of relapse. Am J Hematol 1976
  2. http://dx.doi.org/10.1002/ajh.2830010202 PMid:1069473 2. Burchenal JH, Murphy ML. Long term survivors in acute leukemia. Cancer Res 1965
  3. PMid:5862991 3. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood ALL patients. Results and conclusions of the multicenter trial ALL-BFM ’86. Blood 1994
  4. PMid:7949185 4. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children’s Cancer Group Study CCG-106. J Clin Oncol 1993
  5. PMid:8229139 5. Rivera GK, Raimondi SC, Williams DL, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991
  6. http://dx.doi.org/10.1016/0140-6736(91)90733-6 6. Buchanan GR, Rivera GK, Boyett JM, et al. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group study. Blood 1988
  7. PMid:3167209 7. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991
  8. PMid:1878583 8. Pui CH. Acute lymphoblastic leukemia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT(eds). Williams Hematology, 7th edition. The McGraw-Hill Companies.2006:1321-42. 9. National Cancer Institute. SEER Cancer Statistics Review, 1975-2006. Erişim: http://seer.cancer.gov/csr/1975İ2006/. 10. Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995
  9. 75(8):2186– 95. http://dx.doi.org/10.1002/1097-0142(19950415)75:83.0.CO
  10. F 11. American Cancer Society. Cancer facts and figures 2008. Erişim: http://www.cancer.org. 12. Kutluk T. Çocukluk çağı kanserlerin epidemiolojisi. Klinik Gelişim 2007
  11. Shivakumar R, Tan W, Wilding GE, et al. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia–a review of 101 cases. Ann Oncol 2008
  12. 19(9):1634-8. http://dx.doi.org/10.1093/annonc/mdn182 PMid:18467310 PMCid:2733065 14. Spector LG, Ross JA, Robis